E 2027

Drug Profile

E 2027

Alternative Names: E2027

Latest Information Update: 23 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Inc
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Lewy body disease

Most Recent Events

  • 15 May 2018 Phase-II/III clinical trials in Lewy body disease (In the elderly, In adults) in European Union, Japan, USA (PO) (Eisai pipeline, May 2018) (NCT03467152)
  • 15 Mar 2018 Eisai plans a phase II trial for Dementia in USA, France and United Kingdom in April 2018 , (NCT03467152)
  • 16 Jul 2017 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top